Pitavastatin Yarindo Use In Pregnancy & Lactation

Pregnancy: Teratogenic effects: Pregnancy Category X.
Pitavastatin is contraindicated in women who are pregnant or planning to become pregnant. During pregnancy, blood cholesterol and triglycerides increase, which are crucial for fetal development. Discontinuing lipid-lowering medications during pregnancy has little effect on the treatment of primary hyperlipidemia because atherosclerosis is a chronic disease (see Contraindications). There are no studies on the efficacy and safety of pitavastatin in pregnant women, although there have been reports of congenital abnormalities following intrauterine use of HMG-CoA reductase inhibitors. Pitavastatin can cause fetal harm when administered to pregnant women. If a pregnant woman uses pitavastatin, the patient should be informed of the risk to the fetus and the lack of clinical benefit from continued use during pregnancy.
Nursing Mothers: It is unknown whether Pitavastatin is excreted in human milk; however, small amounts of other drugs in this class have been shown to be excreted in breast milk. Because other drugs in this class are excreted in breast milk and HMG-CoA reductase inhibitors have the potential to cause serious adverse reactions in nursing infants, women requiring Pitavastatin treatment are advised to refrain from breastfeeding or discontinue Pitavastatin use (see Contraindications).